share_log

What the Options Market Tells Us About AbbVie

What the Options Market Tells Us About AbbVie

期權市場告訴我們有關艾伯維公司的信息
Benzinga ·  01:47

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 11 unusual trades.

財務巨頭在艾伯維公司上做出了明顯的看淡舉動。我們對艾伯維公司(紐交所:ABBV)期權歷史的分析顯示出11筆異常交易。

Delving into the details, we found 9% of traders were bullish, while 90% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $454,486, and 5 were calls, valued at $292,034.

深入細節後,我們發現9%的交易者持看好態度,而90%顯示出看淡傾向。在我們發現的所有交易中,有6筆看跌,價值$454,486,有5筆看漲,價值$292,034。

What's The Price Target?

目標價是多少?

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $195.0 and $210.0 for AbbVie, spanning the last three months.

在評估了交易量和未平倉合約後,明顯地看出主要市場參與者的目光集中在艾伯維公司的目標價區間,即$195.0和$210.0之間,涵蓋了過去三個月。

Volume & Open Interest Trends

成交量和未平倉量趨勢

In terms of liquidity and interest, the mean open interest for AbbVie options trades today is 559.88 with a total volume of 4,547.00.

就流動性和利息方面而言,艾伯維公司期權交易今日的平均未平倉合約爲559.88,總成交量爲4,547.00。

In the following chart, we are able to follow the development of volume and open interest of call and put options for AbbVie's big money trades within a strike price range of $195.0 to $210.0 over the last 30 days.

在下圖中,我們可以追蹤過去30天內關於艾伯維公司看漲和看跌期權的成交量和未平倉合約的發展,這些交易集中在$195.0至$210.0的行權價格範圍內。

AbbVie Call and Put Volume: 30-Day Overview

艾伯維公司看漲和看跌成交量:30天總覽

bigjpg

Biggest Options Spotted:

最大的期權交易:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
ABBV CALL SWEEP BEARISH 11/15/24 $1.88 $1.89 $1.89 $207.50 $163.1K 223868
ABBV PUT SWEEP BEARISH 11/22/24 $2.11 $1.78 $2.11 $197.50 $162.2K 1781
ABBV PUT SWEEP BEARISH 11/22/24 $2.25 $1.91 $2.25 $200.00 $78.7K 269245
ABBV PUT SWEEP BEARISH 05/16/25 $11.4 $11.25 $11.4 $200.00 $67.2K 5360
ABBV PUT SWEEP BEARISH 11/22/24 $1.66 $1.59 $1.66 $197.50 $52.2K 11.3K
標的 看跌/看漲 交易類型 情緒 到期日 賣盤 買盤 價格 執行價格 總交易價格 未平倉合約數量 成交量
艾伯維公司 CALL SWEEP BEARISH 11/15/24 $1.88 $1.89 $1.89 $207.50 $163.1K 223868
艾伯維公司 看跌 SWEEP BEARISH 11/22/24 $2.11 1.78美元 $2.11 $197.50 $162.2K 1781
艾伯維公司 看跌 SWEEP BEARISH 11/22/24 2.25美元 $1.91 2.25美元 $200.00 $78.7K 269245
艾伯維公司 看跌 SWEEP BEARISH 05/16/25 $11.4 $11.25 $11.4 $200.00 $67.2K 5360
艾伯維公司 看跌 SWEEP BEARISH 11/22/24 $1.66 $1.59 $1.66 $197.50 52,200 美元 11.3K

About AbbVie

關於艾伯維公司

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

AbbVie是一家藥品公司,其在免疫學(包括Humira、Skyrizi和Rinvoq)和腫瘤學(包括Imbruvica和Venclexta)方面擁有強大的業務。該公司於2013年初從Abbott分拆而來。2020年收購雅培使其在美容業務(包括Botox)中新增了一些產品和藥品。

In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.

考慮到艾伯維公司最近的期權歷史,現在是時候專注於公司本身了。我們的目標是探討其當前的表現。

Where Is AbbVie Standing Right Now?

艾伯維目前處於什麼狀態?

  • With a trading volume of 2,248,728, the price of ABBV is up by 0.19%, reaching $202.07.
  • Current RSI values indicate that the stock is may be approaching overbought.
  • Next earnings report is scheduled for 86 days from now.
  • 艾伯維公司的成交量爲2,248,728,價格上漲0.19%,達到202.07美元。
  • 當前RSI值表明該股票可能接近超買狀態。
  • 下一份業績將於86天后發佈。

Expert Opinions on AbbVie

關於艾伯維公司的專家意見

Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $217.4.

在過去一個月裏,有5位行業分析師分享了對這支股票的見解,提出了平均目標價217.4美元。

Turn $1000 into $1270 in just 20 days?

在短短20天內,將1000美元變成1270美元?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.* An analyst from Morgan Stanley has decided to maintain their Overweight rating on AbbVie, which currently sits at a price target of $231. * An analyst from Citigroup persists with their Buy rating on AbbVie, maintaining a target price of $226. * Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on AbbVie with a target price of $215. * An analyst from BMO Capital has decided to maintain their Outperform rating on AbbVie, which currently sits at a price target of $220. * An analyst from UBS persists with their Neutral rating on AbbVie, maintaining a target price of $195.

20年期期權交易員揭示了他的一行圖表技術,顯示何時買入和賣出。複製他的交易,平均每20天獲利27%。單擊此處訪問。* 摩根士丹利的一位分析師決定維持對艾伯維公司的增持評級,目標價爲231美元。* 花旗集團的一位分析師堅持對艾伯維公司的買入評級,維持目標價爲226美元。* 另一位花旗集團的分析師在評估時保持一貫性,維持對艾伯維公司的買入評級,目標價爲215美元。* 摩根大通的一位分析師決定繼續對艾伯維公司的表現評級,目標價爲220美元。* 瑞士銀行的一位分析師堅持對艾伯維公司的中立評級,維持目標價爲195美元。

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with Benzinga Pro for real-time alerts.

期權交易涉及更大的風險,但也提供了更高利潤的潛力。精明的交易員通過持續的教育、戰略交易調整、利用各種因子,並保持對市場動態的敏銳感來減輕這些風險。通過Benzinga Pro保持最新的艾伯維公司期權交易,即時獲得警報。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論